logo-loader
FinanceBanks
Lloyds Banking Group

Lloyds commences share buyback programme to acquire up to £1.75bn worth of stock for cancellation

The FTSE 100-listed lender said it has appointed with Morgan Stanley and UBS as joint brokers to conduct the share buyback programme on its behalf

Lloyds Bank sign
Lloyds said the buyback would end no later than 31 December 2019

Lloyds Banking Group PLC (LON:LLOY) has commenced a previously announced share buyback program to acquire up to £1.75bn worth of stock for cancellation

In a brief statement, the FTSE 100-listed lender said the buyback would end no later than 31 December 2019.

READ: Lloyds sees 2018 profits miss forecasts after a weak fourth-quarter but still hikes dividend, launches share buyback

Lloyds said it has appointed with Morgan Stanley and UBS as joint brokers to conduct the share buyback programme on its behalf.

It added: “The sole purpose of the program is to reduce the ordinary share capital of the company.”

The bank unveiled the big share buyback program on 2 February when it reported below-forecast 2018 results but pleased investors by still hiking its dividend.

Lloyds said it will pay a total ordinary dividend for 2018 of 3.21p per share, up 5% from 2017.

With the proposed share buyback of up to £1.75bn that represented a total capital return for 2018 of up to £4.0bn, an increase of 26% from 2017’s £3.2bn figure.

Quick facts: Lloyds Banking Group

Price: £0.50

Market: LSE
Market Cap: £35.11 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Scancell back in the clinic with a phase II trial of its...

Scancell Holdings PLC's (LON:SCLP) Cliff Holloway tells Proactive London's Andrew Scott they've begun the UK arm of the phase II trial of its flagship skin cancer treatment. The trial is testing the safety and efficacy of SCIB1 in metastatic melanoma patients who are also receiving Merck’s...

14 hours, 12 minutes ago

RNS

Transaction in Own Shares

10 hours, 4 minutes ago

Transaction in Own Shares

3 days, 10 hours ago

Transaction in Own Shares

4 days, 10 hours ago

Transaction in Own Shares

5 days, 10 hours ago

Transaction in Own Shares

6 days, 10 hours ago

Director/PDMR Shareholding

6 days, 13 hours ago

Transaction in Own Shares

1 week, 1 day ago

Transaction in Own Shares

1 week, 4 days ago

2 min read